Semantic Scholar uses AI to extract papers important to this topic.
This investigation addressed the paradox that disintegrins and small RGD-ligands readily bind to the resting alphaIIbbeta3… Expand Thrombocytopenia is a relatively common side effect observed during glycoprotein (GP) IIb/IIIa antagonist therapy. With the oral… Expand BACKGROUND
It has been expected that therapy with oral glycoprotein (GP) IIb/IIIa blockers including roxifiban will reduce… Expand Roxifiban (DMP 754) is a glycoprotein (GP) IIb/IIIa antagonist. Following oral administration to humans, roxifiban is metabolized… Expand Roxifiban, an experimental antithrombotic prodrug, exists as crystalline forms I and II. A quantitative solid-state nuclear… Expand Roxifiban was found to exist in two polymorphic forms. The polymorphs were detected by X-ray powder diffraction and solid-state… Expand Roxifiban is an ester prodrug that is hydrolyzed, after oral administration, to the active glycoprotein (GP) IIb/IIIa antagonist… Expand This study was undertaken to compare the platelet binding characteristics and anti-platelet efficacy of a nonpeptide glycoprotein… Expand In the present study, the in vitro efficacy of different platelet glycoprotein IIb/IIIa (GPIIb/IIIa) antagonists on platelet… Expand Currently used antiplatelet drugs, including aspirin, ticlopidine, and others, are effective against certain but not all of the… Expand